Monte Rosa Therapeutics, Inc. Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets
Monte Rosa Therapeutics, Inc. (GLUE) reported Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets of 1.35% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets · last filed 2026-03-17
- Monte Rosa Therapeutics, Inc. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2025 was 1.35%, a 35.00% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2024 was 1.00%, a 33.33% decline from fiscal 2023.
- Monte Rosa Therapeutics, Inc. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2023 was 1.50%, a 34.78% decline from fiscal 2022.
- Monte Rosa Therapeutics, Inc. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2022 was 2.30%, a 411.11% increase from fiscal 2021.
| Period end | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets 12 month |
|---|---|
| 2025-12-31 | 1.35% 10-K · filed 2026-03-17 |
| 2024-12-31 | 1.00% 10-K · filed 2026-03-17 |
| 2023-12-31 | 1.50% 10-K · filed 2025-03-20 |
| 2022-12-31 | 2.30% 10-K · filed 2024-03-14 |
| 2021-12-31 | 0.45% 10-K · filed 2023-03-16 |
| 2020-12-31 | 0.45% 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |